Blank control

ApprovedSmall molecule

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Blank control is one of 155 small molecule programs targeting Wound Healing. It is currently in Approved.

Indications

Total Trials

Active Trials

154

Competitors

Pipeline

Status by Indication[3][1]

Indication

Wound HealingActive, not recruiting

Inflammatory ResponseActive, not recruiting

InfluenzaActive, not recruiting

Type 2 DiabetesActive, not recruiting

Heart DiseaseActive, not recruiting

Aortic DissectionActive, not recruiting

Wound HealingPreclinical

Active, not recruiting

Inflammatory ResponsePreclinical

Active, not recruiting

InfluenzaPhase 2

Active, not recruiting

Type 2 DiabetesPreclinical

Active, not recruiting

Heart DiseaseApproved

Active, not recruiting

Aortic DissectionPreclinical

Active, not recruiting

Competition

Competitive Landscape

1053 competitors in Influenza

#DrugCompanyPhaseTrials

Blank control

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Approved

1 2

Fluzone

GSK

Preclinical

37 3

Crestor

AstraZeneca

Preclinical

1 4

Trexall

Alnylam Pharmaceuticals

Preclinical

1 5

Avigan

AAppili Therapeutics Inc.

Preclinical

6 6

Quadrivalent Influenza Vaccine

Sanofi

Preclinical

30 7

COMIRNATY

Pfizer

Preclinical

1 8

Antihistamine

Arrowhead Pharmaceuticals

Preclinical

1 9

Influenza A/H5N1

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

14 10

PD-1/PD-L1 Inhibitors

CChuangzhen Chen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

N/ANot yet recruiting

Wound Healing

NCT07258381

Q4 2030

Post-ApprovalRecruiting

Heart Disease

NCT07110415

Clinical

Trials by Indication[1]

Inflammatory Response1 trial

Protective Effect of Ulinastatin Against Negative Inflammatory Response and Organ Dysfunction After Acute Type a Aortic Dissection Surgery (PANDA I)

Completed·NNanjing Medical University·N/A·NCT04711889·203 enrolled

Heart Disease1 trial

Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction

Recruiting·SSPH Qingdao Growful Pharmacetical Co.,Ltd·Phase 4·NCT07110415·2,708 enrolled

Type 2 Diabetes1 trial

Effect of Henagliflozin on Cardiac Function in Type 2 Diabetes Patients With Chronic Heart Failure (HERO-HF)

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT05742230·1,932 enrolled

Function1 trial

Study on Exploring the Effect of DPP-4 Inhibitors on β-cell Function by Using the Two-step Hyperglycemic Clamp

Unknown status·SShanghai Jiao Tong University School of Medicine·Phase 4·NCT02386943·12 enrolled

LAM1 trial

Study of Comparing the Different Effect of DPP-4 Inhibitors and Sulfonylurea by Using "Biphase-Hyperglycemic Clamp"

Unknown status·SShanghai Jiao Tong University School of Medicine·Phase 4·NCT01660386·12 enrolled

5 more indications

Efficacy and Safety1 trial

A Study on the Efficacy and Safety of Benzonatate Soft Capsules for Improving Adult Cough Symptoms

Unknown status· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 3·NCT03722914·220 enrolled

Influenza1 trial

A Randomized, Double-blind, Placebo-controlled, Multicenter and Phase Ⅱa Clinical Trial for the Effectiveness and Safety of Baicalein Tablets in the Treatment of Improve Other Aspects of Healthy Adult With Influenza Fever

Unknown status· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 2·NCT03830684·180 enrolled

Wound Healing1 trial

Mailuo Shutong Pills for Diabetic Wound Healing: A Multicenter Randomized Trial

Not yet recruiting·PPeking University Third Hospital·N/A·NCT07258381·56 enrolled

Cardiovascular Surgery1 trial

Protective Effect of Sivelestat Against Negative Pulmonary Function and Organ Dysfunction After Cardiovascular Surgery (PANDA VI)

Recruiting·NNanjing Medical University·N/A·NCT06195267·500 enrolled

Aortic dissection1 trial

Protective Effect of Thymosin Α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA II)

Recruiting·NNanjing Medical University·N/A·NCT05339529·330 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Blank control. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Blank control compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Blank control. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CSPC ZhongQi Pharmaceutical Technology Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Blank control

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q4 2030

Trials by Indication[1]

Inflammatory Response1 trial

Heart Disease1 trial

Type 2 Diabetes1 trial

Function1 trial

LAM1 trial

Efficacy and Safety1 trial

Influenza1 trial

Wound Healing1 trial

Cardiovascular Surgery1 trial

Aortic dissection1 trial

References

Drug Info

Quick Facts

Related News